MEA In-Vitro Toxicology Testing Market

MEA In-Vitro Toxicology Testing Market Size (2023 to 2028)

The In-vitro toxicology testing market in Middle East & Africa is expected to reach USD 7603.99 Million by 2028 from USD 2795.06 Million in 2023, growing at a CAGR of 22.16% from 2023 to 2028.

In-vitro toxicology testing is the scientific analysis of toxic effects produced by chemical substances on cultured mammalian cells or bacteria. Toxicity testing is essential in drug discovery as it identifies the toxic effects of a new compound in the early stages of drug discovery. This early detection of toxicity reduces the development cost and time.

One of the key drivers boosting the market is significant breakthroughs in toxicity science. In addition, the MEA market for in-vitro toxicity testing is expected to rise due to the high costs connected with traditional animal tests and socio-ethical problems related to animal tests. In-vitro toxicology assays for evaluating drug product safety and assessing the possible effect of medicines on cells and tissues are expected to boost revenue creation in the market. Companies have diversified their portfolios to meet demand in the market for in-vitro toxicology testing, as the demand for such tests has grown. Market stability is projected to be enhanced by significant government support for research combined with clear reimbursement rules to produce automated and technologically advanced equipment for laboratory analysis and ex-vivo testing.

The availability of various tools in the biotechnology and bioinformatics divisions for conducting in-silico simulations on animal models is another key factor, which is expected to accelerate the growth rate of the MEA In-vitro toxicology testing market. Furthermore, the creation of toxicological databases for the in-silico study of various chemicals is expected to increase demand for in-vitro procedures, resulting in industry advancement. Due to an increase in the number of R&D procedures that require in vitro testing, a restriction on animal testing, and increased awareness about environmental concerns, the MEA in vitro toxicity testing market is likely to develop significantly throughout the period. Furthermore, advancements in genetics and genetic screening technologies and the advent of innovative 3D cell culture approaches are expected to increase the in vitro toxicity testing industry. To address the specific criteria of the researchers, large firms have focused on new product launches. Rapid advancements in biomedical sciences are expected to develop newer and more advanced in-vitro test methodologies for hazard characterization. Toxicity testing is gradually improving with the help of many new technologies. It is currently well-positioned to benefit from promising biotechnology revolutions.

However, a lack of immunity testing and immunological stimulation in present in-vitro tests are expected to restrict the market’s growth rate. The existing regulatory guideline for in-vitro toxicity testing does not address specific study designs. In-vitro testing techniques and data documentation should be thorough, repeatable, and include particular analytical methods, as well as documentation of assay procedures and outcomes. As a result, the in-vitro toxicology testing's growth is being hampered by these strict requirements. A lack of understanding of the underlying scientific principles and the proper procedure selection may result in various direct and indirect costs, increasing the workload and time pressure on researchers and service providers. As a result, highly qualified professionals are required for method development, validation, operation, and troubleshooting.

This research report on the Middle East and Africa In-Vitro Toxicology Testing Market has been segmented and sub-segmented into the following categories:

By Product

• Assays
• Reagents & Labware
• Services
• Growth Hormone Therapy

By Type

• ADME (Absorption, Distribution, Metabolism, and Excretion)
• Dose
• Toxic Substance

By Toxicity Endpoints & Tests

• Systemic Toxicity
• Dermal Toxicity
• Carcinogenicity
• Ocular Toxicity
• Skin Sensitization & Irritation
• Genotoxicity
• Neurotoxicity
• Organ Toxicity
• Other Toxicity Endpoints & Tests

By Technology

• OMICS Technologies
• Cell Culture Technology
• High-Throughput Technologies
• Molecular Imaging Technologies 

By Method

• In-Silico Methods
• Biochemical Assays
• Cellular Assays
• Ex-Vivo Models

By Industry

• Cosmetics and Household Products
• Diagnostics
• Pharmaceuticals
• Food Industry
• Chemicals

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Increased government focus on drug research, increased healthcare spending, and the provision of suitable infrastructure for drug discovery technology growth and development Furthermore, strict regulatory standards governing medication development and approval have expanded the use of in-vitro toxicology testing services in the Middle East and Africa regional market.

KEY MARKET PLAYERS:

A few of the prominent companies operating in the MEA In-Vitro Toxicology Testing Market profiled in this report are Covance, Inc.  (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), General Electric Company (U.S.), BioReliance, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.) and Cyprotex (U.K.)